Evidence map›Paper›PMID 40111543›Full record

ReviewCurrent cardiology reports2025

Bioengineering Approaches to In Vitro Modeling of Genetic and Acquired Cardiac Diseases.

Linqi Jin, Boeun Hwang, Sarah Rezapourdamanab, Vani Sridhar, Roshni Nandwani, Mehdi Salar Amoli, Vahid Serpooshan

Abstract readReview
In one paragraph

Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Gene- and cell-based therapy in cardiovascular diseases.Journal of cardiovascular pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Linqi JinDepartment of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Boeun HwangDepartment of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Sarah RezapourdamanabDepartment of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Vani SridharDepartment of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Roshni NandwaniDepartment of Biology, Emory University, Atlanta, GA, 30322, USA.
Mehdi Salar AmoliDepartment of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Vahid SerpooshanDepartment of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, 30322, USA. vahid.serpoosahan@bme.gatech.edu.

Funding

Supplement of HL131017: Myocardial remuscularization by cardiac patch delivery of epicardial FSTL1 and CCND2 overexpressing cardiomyocytesR01HL131017 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SERPOOSHAN, VAHID, ZHANG, JIANYI · 2016 to 2025
$5.8M
CBT@EmTech - CardioVascular Biomechanics Training Program at Emory and GaTechT32HL166146 · NHLBI · EMORY UNIVERSITY · PI Lakshmi Prasad Dasi, Hanjoong Jo · 2023 to 2026
$1.3M
National Science Foundation 2044657NHLBI NIH HHS R01 HL131017NHLBI NIH HHS T32 HL166146NIH HHS R01 HL131017NIH HHS T32 HL166146
6 · The paper itself

Abstract

purpose of reviewThis review aims to explore recent advancements in bioengineering approaches used in developing and testing in vitro cardiac disease models. It seeks to find out how these tools can address the limitations of traditional in vitro models and be applied to improve our understanding of cardiac disease mechanisms, facilitate preclinical drug screening, and equip the development of personalized therapeutics. RECENT

findingsHuman induced pluripotent stem cells have enabled the generation of diverse cardiac cell types and patient-specific models. Techniques like 3D tissue engineering, heart-on-a-chip platforms, biomechanical conditioning, and CRISPR-based gene editing have enabled faithful recreation of complex cardiac microenvironments and disease conditions. These models have advanced the study of both genetic and acquired cardiac disorders. Bioengineered in vitro models are transforming the basic science and clinical research in cardiovascular disease by improving the biomimicry and complexity of tissue analogues, increasing throughput and reproducibility of screening platforms, as well as offering patient and disease specificity. Despite challenges in scalability and functional maturity, integrating multiple bioengineering techniques with advanced analytical tools in in vitro modeling platforms holds promise for future precision and personalized medicine and therapeutic innovations.

Indexed as

BioengineeringHeart DiseasesTissue EngineeringGene EditingHumansInduced Pluripotent Stem CellsCardiac diseasesCRISPR/Cas9Heart-on-a-chipHuman induced pluripotent stem cell (iPSC)In vitro modelTissue engineering

Identifiers

PMID40111543
PMCPMC11926001

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.